Jonathan Violin
CIK 1730615 · Chief Executive Officer · last filed 2026-06-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$9.13M
Companies
7
Total Filings
26
Lifetime Open-Market Net
-$6.11M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Director | — | $15.70 | — | $0 | 2 | 2026-06-03 |
| DNTH | Director | — | $106.33 | — | $0 | 4 | 2026-05-22 |
| Astria Therapeutics, Inc. (ATXS) Delisted | Director | 0 | $12.58 | $0 | $0 | 7 | 2026-01-23 |
| VRDN | Chief Executive Officer | 480,905 | $18.98 | $9.13M | -$6.11M | 9 | 2023-02-07 |
| Astria Therapeutics, Inc. (CATB) Delisted | Director | — | $8.54 | — | $0 | 2 | 2021-06-02 |
| Viridian Therapeutics, Inc.\DE (MGEN) Delisted | President and COO | 50,124 | — | — | $0 | 1 | 2020-10-30 |
| TREVENA INC (TRVN) Delisted | SVP-Scientific Affairs & IR | — | $0.01 | — | $0 | 1 | 2018-03-02 |
Recent Filings · Page 3 of 3
26 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-09-22 | Astria Therapeutics, Inc. (ATXS) Delisted | Other (J) | — | $0 | EDGAR |
| 2021-06-02 | Astria Therapeutics, Inc. (CATB) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-02-01 | Astria Therapeutics, Inc. (CATB) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-01-20 | VRDN | Grant (A) | — | $0 | EDGAR |
| 2020-10-30 | Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Other (J) | +50,124 | $0 | EDGAR |
| 2018-03-02 | TREVENA INC (TRVN) Delisted | Grant (A) | — | $0 | EDGAR |
Showing 21–26 of 26
Prev
Page 3 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.